Aspirin cost-effectiveness
This article was originally published in The Tan Sheet
Executive Summary
Increased use of aspirin for secondary prevention of coronary heart disease "is attractive from a cost-effectiveness perspective," while treatment with Rx clopidogrel "is currently unattractive" due to its high price, according to June 6 NEJM. Jean-Michel Gaspoz, MD, et al., Hopitaux Universitaires, Geneva, estimated incremental cost effectiveness from 2003-2007 of four strategies in CHD patients over 35. Researchers found extension of aspirin therapy from current levels of use to all eligible patients "would have an estimated cost-effectiveness ratio of about $11,000 per quality-adjusted year of life gained." Clopidogrel alone would have incremental cost of over $130,000, researchers say...
You may also be interested in...
Aspirin Demonstrates Cost Benefit Versus Statins In Heart Disease – Study
Aspirin use for coronary heart disease prevention in a patient with a 5% five-year coronary risk costs less than one-fifth per event prevented than simvastatin (J&J/Merck's Zocor) in a patient at a 30% five-year risk, a British study found
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.